A Phase I/II, Multicentre, Open-label Study of EGFRmut-TKI EGF816, Administered Orally in Adult Patients With EGFRmut Solid Malignancies
To estimate the maximum tolerated dose (MTD) or recommended phase II dose (RP2D) (Phase l
part) of EGF816 and to investigate the anti-tumour activity of EGF816 (Phase II part).
View this trial on ClinicalTrials.gov
Print this page and take it to your doctor to discuss your eligibilty and treatment options. Only your doctor can refer you to a clinical trial.
These resources are provided in partnership with the
Canadian Cancer Society